Table 1.
Demographic and Clinical Characteristics of Study Sample (n=129)
| Variable | % (n)or Mean (±SD) |
|---|---|
| Sex: Men | 6.2% (8) |
| Women | 93.8% (121) |
| Caucasian race | 52.7% (68) |
| Age, years | 45.4 ± 10.9 |
| BMI, kg/m2 | 27.9 ± 8.0 |
| Weight: Normal (BMI < 25 kg/m2) | 42.6%(55) |
| Overweight (BMI 25.0–29.9 kg/m2) | 27.1% (35) |
| Obese (BMI ≥ 30 kg/m2) | 30.2%(39) |
| SELENA-SLEDAI | 2.4 ± 2.8 |
| SLICC/ACR | 1.7 ± 2.2 |
| Medications | |
| Anti-malarials | 84.5% (109) |
| Steroids (mean dose 10.6mg) | 47.3% (61) |
| Immunosuppressivesa | |
| Mycophenolate Mofetil | 17.8% (23) |
| Azathioprine | 10.9% (14) |
| Methotrexate | 10.9% (14) |
| Cyclosporin | 0.8% (1) |
| Leflunomide | 0.8% (1) |
| Tacrolimus | 0.8% (1) |
SD: Standard deviation; BMI: Body Mass Index; SELENA-SLEDAI: Safety of Estrogen in Lupus Erythematosus National Assessment-SLE Disease Activity Index; SLICC: Systemic Lupus International Collaborative Clinics/ACR Damage Index; IPAQ: International Physical Activity Questionnaire
a
No patients were on Cyclophosphamide